drugset / Trial / NCT01071512

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512

Completed 20 enrolled University of Chicago Biogen · collab
NaSingle-groupOpen-labelTreatment

Summary

The long-term objective is to further establish the role of Tysabri in preventing neurological degeneration in multiple sclerosis (MS) and to establish powerful and efficient new markers for neurological degeneration in MS. The study intends to correlate cognition with two instruments and their measurements-MRI and OCT (optical coherence tomography).

Timeline

Start
2010-04
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody 300 mg Intravenous

Indications